WO2008092134A3 - Tumor-specific antigens, cytotoxic t lymphocytes responsive thereto, and methods of using the same - Google Patents

Tumor-specific antigens, cytotoxic t lymphocytes responsive thereto, and methods of using the same Download PDF

Info

Publication number
WO2008092134A3
WO2008092134A3 PCT/US2008/052132 US2008052132W WO2008092134A3 WO 2008092134 A3 WO2008092134 A3 WO 2008092134A3 US 2008052132 W US2008052132 W US 2008052132W WO 2008092134 A3 WO2008092134 A3 WO 2008092134A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tumor
same
cytotoxic
specific antigens
Prior art date
Application number
PCT/US2008/052132
Other languages
French (fr)
Other versions
WO2008092134A2 (en
Inventor
James P Allison
Peter A Savage
Original Assignee
Sloan Kettering Inst Cancer
James P Allison
Peter A Savage
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, James P Allison, Peter A Savage filed Critical Sloan Kettering Inst Cancer
Publication of WO2008092134A2 publication Critical patent/WO2008092134A2/en
Publication of WO2008092134A3 publication Critical patent/WO2008092134A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides tumor-specific class I MHC presented peptides and methods of using the same, as well as cytotoxic T lymphocytes (CTLs) responsive to tumor-specific class I MHC presented peptides and methods of using the same.
PCT/US2008/052132 2007-01-26 2008-01-25 Tumor-specific antigens, cytotoxic t lymphocytes responsive thereto, and methods of using the same WO2008092134A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88689707P 2007-01-26 2007-01-26
US60/886,897 2007-01-26
US1517207P 2007-12-19 2007-12-19
US61/015,172 2007-12-19

Publications (2)

Publication Number Publication Date
WO2008092134A2 WO2008092134A2 (en) 2008-07-31
WO2008092134A3 true WO2008092134A3 (en) 2008-11-27

Family

ID=39645217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/052132 WO2008092134A2 (en) 2007-01-26 2008-01-25 Tumor-specific antigens, cytotoxic t lymphocytes responsive thereto, and methods of using the same

Country Status (1)

Country Link
WO (1) WO2008092134A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019514939A (en) * 2016-04-26 2019-06-06 クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． Therapeutic induction of innate immune response in target tissues

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010777A1 (en) * 1996-09-12 1998-03-19 The General Hospital Corporation Nucleosome-based anti-tumor compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010777A1 (en) * 1996-09-12 1998-03-19 The General Hospital Corporation Nucleosome-based anti-tumor compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAVAGE PETER A ET AL: "Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8(+) T lymphocytes", SCIENCE (WASHINGTON D C), vol. 319, no. 5860, January 2008 (2008-01-01), pages 215 - 220, XP002494713, ISSN: 0036-8075 *
THEODORE J. TSOMIDES ET AL.: "T-cell antigens in cancer", PROC. NATL. ACAD. SCI. USA, vol. 91, April 1994 (1994-04-01), pages 3487 - 3489, XP002494714 *

Also Published As

Publication number Publication date
WO2008092134A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2008103947A3 (en) Activation of human antigen-presenting cells through clec-6
WO2009022154A3 (en) Peptide with multiple epitopes
UA104005C2 (en) 2-oxo-1,2-dihydro-quinoline modulators of immune function
NZ602119A (en) Peptide vaccines for cancers expressing tumor-associated antigens
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
MX345909B (en) Anti-fgfr3 antibodies and methods using same.
WO2009031043A3 (en) Compositions comprising yersinia pestis antigens
GEP20227342B (en) Formulations of rifaximin and uses thereof
EA201100268A1 (en) VACCINE
MX2018015285A (en) Anti-b7-h3 antibodies and antibody drug conjugates.
WO2008121767A3 (en) Stitched polypeptides
MY171841A (en) Antibody formulation
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
WO2006082406A3 (en) Human antibodies and proteins
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2014071402A8 (en) Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
MX2018015277A (en) Anti-b7-h3 antibodies and antibody drug conjugates.
WO2011032161A3 (en) Vaccines directed to langerhans cells
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
WO2008094599A3 (en) Modified rna ligase for efficient 3' modification of rna
WO2008121894A3 (en) Endogenous expression of hla-g and/or hla-e by mesenchymal cells
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2009135199A3 (en) Vaccine compositions and methods

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08728355

Country of ref document: EP

Kind code of ref document: A2